Skip to main content
Top
Published in: International Urology and Nephrology 7/2016

01-07-2016 | Nephrology - Original Paper

Urine and serum ghrelin, sCD80 and sCTLA-4 levels in doxorubicin-induced experimental nephrotic syndrome

Authors: Duygu Ozkorucu, Nuran Cetin, Nadide Melike Sav, Bilal Yildiz

Published in: International Urology and Nephrology | Issue 7/2016

Login to get access

Abstract

Background

Nephrotic syndrome (NS) is an immune-mediated disorder associated with hyperlipidemia. NS has been proposed to be mediated through CD80-related T cell immune response, which could be blocked using soluble cytotoxic T lymphocyte-associated s(CTLA)-4. Although ghrelin is a hormone-modulating lipid metabolism and suppressing immune system, the precise role of ghrelin in NS is not well established.

Methods

We evaluated the levels of ghrelin, soluble CD80 (sCD80) and sCTLA4 in serum and urine in doxorubicin-induced NS in rats. We also investigated the relation between their levels and the levels of serum total cholesterol (TC), triglyceride, albumin and urine protein.

Results

While urinary ghrelin levels were significantly lower in the nephrotic rats compared to the control group, serum ghrelin levels were comparable in the nephrotic and control rats. In contrast, serum and urinary sCD80 and sCTLA4 levels were higher in the nephrotic rats than the controls. The urinary ghrelin levels were negatively correlated with the levels of serum triglyceride, TC and urine protein, sCD80 and sCTLA4. The urine sCD80 levels were positively correlated with the TC, urine protein and urine sCTLA4 levels, and negatively correlated with the serum albumin. The urine sCTLA4 levels were positively correlated with the TC and urine protein levels and negatively correlated with the serum albumin levels. In regression analysis, the urine ghrelin levels significantly relate to urine sCD80 levels. Besides, hyperlipidemia in NS did not appear to be related to serum ghrelin levels.

Conclusion

Low urine ghrelin levels might be relevant to pathogenesis of doxorubicin-induced NS. The reduction in urine ghrelin levels might also be associated with increased levels of urine sCTLA4 and sCD80 which reflect proteinuria.
Literature
1.
go back to reference Hosoda H, Kojima M, Kangawa K (2006) Biological, physiological, and pharmacological aspects of ghrelin. J Pharmacol Sci 100:398–410CrossRefPubMed Hosoda H, Kojima M, Kangawa K (2006) Biological, physiological, and pharmacological aspects of ghrelin. J Pharmacol Sci 100:398–410CrossRefPubMed
2.
go back to reference Verhulst PJ, Depoortere I (2012) Ghrelin’s second life: from appetite stimulator to glucose regulator. World J Gastroenterol 18:3183–3195PubMedPubMedCentral Verhulst PJ, Depoortere I (2012) Ghrelin’s second life: from appetite stimulator to glucose regulator. World J Gastroenterol 18:3183–3195PubMedPubMedCentral
4.
go back to reference Lim CT, Kola B, Korbonits M (2011) The ghrelin/GOAT/GHS-R system and energy metabolism. Rev Endocr Metab Disord 12:173–186CrossRefPubMed Lim CT, Kola B, Korbonits M (2011) The ghrelin/GOAT/GHS-R system and energy metabolism. Rev Endocr Metab Disord 12:173–186CrossRefPubMed
5.
go back to reference Nogueiras R, Wiedmer P, Perez-Tilve D, Veyrat-Durebex C, Keogh JM, Sutton GM, Pfluger PT, Castaneda TR, Neschen S, Hofmann SM et al (2007) The central melanocortin system directly controls peripheral lipid metabolism. J Clin Investig 117:3475–3488CrossRefPubMedPubMedCentral Nogueiras R, Wiedmer P, Perez-Tilve D, Veyrat-Durebex C, Keogh JM, Sutton GM, Pfluger PT, Castaneda TR, Neschen S, Hofmann SM et al (2007) The central melanocortin system directly controls peripheral lipid metabolism. J Clin Investig 117:3475–3488CrossRefPubMedPubMedCentral
6.
go back to reference Andrews ZB, Erion DM, Beiler R, Choi CS, Shulman GI, Horvath TL (2010) Uncoupling protein-2 decreases the lipogenic actions of ghrelin. Endocrinology 151:2078–2086CrossRefPubMedPubMedCentral Andrews ZB, Erion DM, Beiler R, Choi CS, Shulman GI, Horvath TL (2010) Uncoupling protein-2 decreases the lipogenic actions of ghrelin. Endocrinology 151:2078–2086CrossRefPubMedPubMedCentral
7.
go back to reference Perez-Tilve D, Hofmann SM, Basford J, Nogueiras R, Pfluger PT, Patterson JT, Grant E, Wilson-Perez HE, Granholm NA, Arnold M, Trevaskis JL, Butler AA, Davidson WS, Woods SC, Benoit SC, Sleeman MW, DiMarchi RD, Hui DY, Tschöp MH (2010) Melanocortin signaling in the CNS directly regulates circulating cholesterol. Nat Neurosci 13:877–882CrossRefPubMedPubMedCentral Perez-Tilve D, Hofmann SM, Basford J, Nogueiras R, Pfluger PT, Patterson JT, Grant E, Wilson-Perez HE, Granholm NA, Arnold M, Trevaskis JL, Butler AA, Davidson WS, Woods SC, Benoit SC, Sleeman MW, DiMarchi RD, Hui DY, Tschöp MH (2010) Melanocortin signaling in the CNS directly regulates circulating cholesterol. Nat Neurosci 13:877–882CrossRefPubMedPubMedCentral
8.
go back to reference Cheyuo C, Jacob A, Wang P (2012) Ghrelin-mediated sympathoinhibition and suppression of inflammation in sepsis. Am J Physiol Endocrinol Metab 1(302):E265–E272CrossRef Cheyuo C, Jacob A, Wang P (2012) Ghrelin-mediated sympathoinhibition and suppression of inflammation in sepsis. Am J Physiol Endocrinol Metab 1(302):E265–E272CrossRef
9.
go back to reference Granado M, Priego T, Martin AI, Villanua MA, Lopez-Calderon A (2005) Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab 288:486–492CrossRef Granado M, Priego T, Martin AI, Villanua MA, Lopez-Calderon A (2005) Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab 288:486–492CrossRef
10.
go back to reference Souza-Moreira L, Campos-Salinas J, Caro M, Gonzalez-Rey E (2011) Neuropeptides as pleiotropic modulators of the immune response. Neuroendocrinology 94:89–100CrossRefPubMed Souza-Moreira L, Campos-Salinas J, Caro M, Gonzalez-Rey E (2011) Neuropeptides as pleiotropic modulators of the immune response. Neuroendocrinology 94:89–100CrossRefPubMed
11.
go back to reference Rajan D, Wu R, Shah KG, Jacob A, Coppa GF, Wang P (2012) Human ghrelin protects animals from renal ischemia-reperfusion injury through the vagus nerve. Surgery 151:37–47CrossRefPubMed Rajan D, Wu R, Shah KG, Jacob A, Coppa GF, Wang P (2012) Human ghrelin protects animals from renal ischemia-reperfusion injury through the vagus nerve. Surgery 151:37–47CrossRefPubMed
12.
go back to reference Khowailed A, Younan SM, Ashour H, Kamel AE, Sharawy N (2015) Effects of ghrelin on sepsis induced acute kidney injury: one step forward. Clin Exp Nephrol 19:419–426CrossRefPubMed Khowailed A, Younan SM, Ashour H, Kamel AE, Sharawy N (2015) Effects of ghrelin on sepsis induced acute kidney injury: one step forward. Clin Exp Nephrol 19:419–426CrossRefPubMed
13.
go back to reference Baatar D, Patel K, Taub DD (2011) The effects of ghrelin on inflammation and the immune system. Mol Cell Endocrinol 20(340):44–58CrossRef Baatar D, Patel K, Taub DD (2011) The effects of ghrelin on inflammation and the immune system. Mol Cell Endocrinol 20(340):44–58CrossRef
14.
go back to reference Elie V, Fakhoury M, Deschênes G, Jacqz-Aigrain E (2012) Physiopathology of idiopathic nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives. Pediatr Nephrol 27:1249–1256CrossRefPubMed Elie V, Fakhoury M, Deschênes G, Jacqz-Aigrain E (2012) Physiopathology of idiopathic nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives. Pediatr Nephrol 27:1249–1256CrossRefPubMed
15.
go back to reference Shimada M, Araya C, Rivard C, Ishimoto T, Johnson RJ, Garin EH (2011) Minimal change disease: a“two-hit”podocyte immune disorder? Pediatr Nephrol 26:645–649CrossRefPubMed Shimada M, Araya C, Rivard C, Ishimoto T, Johnson RJ, Garin EH (2011) Minimal change disease: a“two-hit”podocyte immune disorder? Pediatr Nephrol 26:645–649CrossRefPubMed
16.
go back to reference Cara-Fuentes G, Wasserfall CH, Wang H, Johnson RJ, Garin EH (2014) Minimal change disease: a dysregulation of the podocyte CD80-CTLA-4 axis? Pediatr Nephrol 29:2333–2340CrossRefPubMedPubMedCentral Cara-Fuentes G, Wasserfall CH, Wang H, Johnson RJ, Garin EH (2014) Minimal change disease: a dysregulation of the podocyte CD80-CTLA-4 axis? Pediatr Nephrol 29:2333–2340CrossRefPubMedPubMedCentral
17.
go back to reference Ling C, Liu X, Shen Y, Chen Z, Fan J, Jiang Y, Meng Q (2015) Urinary CD80 levels as a diagnostic biomarker of minimal change disease. Pediatr Nephrol 30:309–316CrossRefPubMed Ling C, Liu X, Shen Y, Chen Z, Fan J, Jiang Y, Meng Q (2015) Urinary CD80 levels as a diagnostic biomarker of minimal change disease. Pediatr Nephrol 30:309–316CrossRefPubMed
18.
go back to reference Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA (2011) Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev 241:180–205CrossRefPubMedPubMedCentral Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA (2011) Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev 241:180–205CrossRefPubMedPubMedCentral
19.
go back to reference Ishimoto T, Shimada M, Araya CE, Huskey J, Garin EH, Johnson RJ (2011) Minimal change disease: a CD80 podocytopathy? Semin Nephrol 31:320–325CrossRefPubMed Ishimoto T, Shimada M, Araya CE, Huskey J, Garin EH, Johnson RJ (2011) Minimal change disease: a CD80 podocytopathy? Semin Nephrol 31:320–325CrossRefPubMed
20.
go back to reference Lee VW, Harris DC (2011) Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrology 16:30–38CrossRefPubMed Lee VW, Harris DC (2011) Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrology 16:30–38CrossRefPubMed
21.
go back to reference Ebal E, Cavalié H, Michaux O, Lac G (2007) Effect of a lipid-enriched diet on body composition and some regulatory hormones of food intake in growing rats. Ann Endocrinol (Paris) 68:366–371CrossRef Ebal E, Cavalié H, Michaux O, Lac G (2007) Effect of a lipid-enriched diet on body composition and some regulatory hormones of food intake in growing rats. Ann Endocrinol (Paris) 68:366–371CrossRef
22.
go back to reference Zhang Z, Li Q, Liu F, Sun Y, Zhang J (2010) Prevention of diet-induced obesity by safflower oil: insights at the levels of PPARalpha, orexin, and ghrelin gene expression of adipocytes in mice. Acta Biochim Biophys Sin (Shanghai) 15(42):202–208CrossRef Zhang Z, Li Q, Liu F, Sun Y, Zhang J (2010) Prevention of diet-induced obesity by safflower oil: insights at the levels of PPARalpha, orexin, and ghrelin gene expression of adipocytes in mice. Acta Biochim Biophys Sin (Shanghai) 15(42):202–208CrossRef
23.
go back to reference Aydin S, Sahin I, Ozkan Y, Dag E, Gunay A, Guzel SP, Catak Z, Ozercan MR (2012) Examination of the tissue ghrelin expression of rats with diet-induced obesity using radioimmunoassay and immunohistochemical methods. Mol Cell Biochem 365:165–173CrossRefPubMed Aydin S, Sahin I, Ozkan Y, Dag E, Gunay A, Guzel SP, Catak Z, Ozercan MR (2012) Examination of the tissue ghrelin expression of rats with diet-induced obesity using radioimmunoassay and immunohistochemical methods. Mol Cell Biochem 365:165–173CrossRefPubMed
24.
go back to reference Saverino Daniele, Simone Rita, Bagnasco Marcello, Pesce Giampaola (2010) The soluble CTLA-4 receptor and its role in autoimmune diseases: an update. Autoimmun Highlights 1:73–81CrossRef Saverino Daniele, Simone Rita, Bagnasco Marcello, Pesce Giampaola (2010) The soluble CTLA-4 receptor and its role in autoimmune diseases: an update. Autoimmun Highlights 1:73–81CrossRef
25.
go back to reference Taub DD (2008) Novel connections between the neuroendocrine and immune systems: the ghrelin immunoregulatory network. Vitam Hormon 77:325–346CrossRef Taub DD (2008) Novel connections between the neuroendocrine and immune systems: the ghrelin immunoregulatory network. Vitam Hormon 77:325–346CrossRef
26.
go back to reference Cheyuo C, Wu R, Zhou M, Jacob A, Coppa G, Wang P (2011) Ghrelin suppresses inflammation and neuronal nitric oxide synthase in focal cerebral ischemia via the vagus nerve. Shock 35:258–265CrossRefPubMed Cheyuo C, Wu R, Zhou M, Jacob A, Coppa G, Wang P (2011) Ghrelin suppresses inflammation and neuronal nitric oxide synthase in focal cerebral ischemia via the vagus nerve. Shock 35:258–265CrossRefPubMed
27.
28.
go back to reference Garin EH, Diaz LN, Mu W, Wasserfall C, Araya C, Segal M, Johnson RJ (2009) Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol 20:260–266CrossRefPubMedPubMedCentral Garin EH, Diaz LN, Mu W, Wasserfall C, Araya C, Segal M, Johnson RJ (2009) Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol 20:260–266CrossRefPubMedPubMedCentral
29.
go back to reference Sakthivel P, Wermeling F, Elmgren A, Hulthe J, Kakoulidou M, Lefvert AK, Lind L (2010) Circulating soluble CTLA-4 is related to inflammatory markers in the 70 year old population. Scand J Clin Lab Investig 70:237–243CrossRef Sakthivel P, Wermeling F, Elmgren A, Hulthe J, Kakoulidou M, Lefvert AK, Lind L (2010) Circulating soluble CTLA-4 is related to inflammatory markers in the 70 year old population. Scand J Clin Lab Investig 70:237–243CrossRef
30.
go back to reference Li JY, Yong TY, Michael MZ, Gleadle JM (2010) Review: the role of microRNAs in kidney disease. Nephrology (Carlton) 15:599–608CrossRef Li JY, Yong TY, Michael MZ, Gleadle JM (2010) Review: the role of microRNAs in kidney disease. Nephrology (Carlton) 15:599–608CrossRef
31.
go back to reference Luo Y, Wang C, Chen X, Zhong T, Cai X, Chen S, Shi Y, Hu J, Guan X, Xia Z, Wang J, Zen K, Zhang CY, Zhang C (2013) Increased serum and urinary microRNAs in children with idiopathic nephrotic syndrome. Clin Chem 59:658–666CrossRefPubMed Luo Y, Wang C, Chen X, Zhong T, Cai X, Chen S, Shi Y, Hu J, Guan X, Xia Z, Wang J, Zen K, Zhang CY, Zhang C (2013) Increased serum and urinary microRNAs in children with idiopathic nephrotic syndrome. Clin Chem 59:658–666CrossRefPubMed
32.
go back to reference Khella HW, Bakhet M, Lichner Z, Romaschin AD, Jewett MA, Yousef GM (2013) MicroRNAs in kidney disease: an emerging understanding. Am J Kidney Dis 61:798–808CrossRefPubMed Khella HW, Bakhet M, Lichner Z, Romaschin AD, Jewett MA, Yousef GM (2013) MicroRNAs in kidney disease: an emerging understanding. Am J Kidney Dis 61:798–808CrossRefPubMed
Metadata
Title
Urine and serum ghrelin, sCD80 and sCTLA-4 levels in doxorubicin-induced experimental nephrotic syndrome
Authors
Duygu Ozkorucu
Nuran Cetin
Nadide Melike Sav
Bilal Yildiz
Publication date
01-07-2016
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 7/2016
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-016-1249-4

Other articles of this Issue 7/2016

International Urology and Nephrology 7/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.